KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
12.09
+0.34 (2.89%)
Apr 17, 2025, 4:00 PM EDT - Market closed
KalVista Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for KalVista Pharmaceuticals stock have an average target of 24.83, with a low estimate of 19 and a high estimate of 30. The average target predicts an increase of 105.38% from the current stock price of 12.09.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for KalVista Pharmaceuticals stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 4 | 5 | 5 | 5 | 5 |
Buy | 1 | 2 | 3 | 3 | 3 | 3 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 6 | 8 | 8 | 8 | 8 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Needham | Needham | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +131.60% | Apr 8, 2025 |
Needham | Needham | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +131.60% | Mar 26, 2025 |
Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $19 | Buy | Reiterates | $19 | +57.15% | Mar 26, 2025 |
Jones Trading | Jones Trading | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +148.14% | Mar 26, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +65.43% | Mar 14, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
31.44M
EPS This Year
-3.60
from -3.44
EPS Next Year
-3.07
from -3.60
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
---|---|---|---|---|---|---|
High | n/a | 58.2M | 148.2M | |||
Avg | n/a | 31.4M | 112.2M | |||
Low | n/a | 15.4M | 43.1M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
---|---|---|---|---|---|---|
High | - | - | 371.4% | |||
Avg | - | - | 256.9% | |||
Low | - | - | 37.1% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
---|---|---|---|---|---|---|
High | -3.51 | -2.53 | -1.04 | |||
Avg | -3.60 | -3.07 | -1.62 | |||
Low | -3.59 | -3.68 | -2.36 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.